136 related articles for article (PubMed ID: 36884333)
1. Dupilumab in Patients with Eosinophilic Esophagitis. Reply.
Dellon ES; Rothenberg ME; Bredenoord AJ
N Engl J Med; 2023 Mar; 388(10):956-957. PubMed ID: 36884333
[No Abstract] [Full Text] [Related]
2. Dupilumab in Patients with Eosinophilic Esophagitis.
Greuter T; Schoepfer AM
N Engl J Med; 2023 Mar; 388(10):955-956. PubMed ID: 36884332
[No Abstract] [Full Text] [Related]
3. Dupilumab for the Treatment of Adult and Adolescent Patients With Eosinophilic Esophagitis.
Trogen B; Baker MG
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2618-2619. PubMed ID: 37558363
[No Abstract] [Full Text] [Related]
4. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
5. Strategies for the Use of Dupilumab in Eosinophilic Esophagitis.
Sauer BG; Barnes BH; McGowan EC
Am J Gastroenterol; 2023 May; 118(5):780-783. PubMed ID: 36716447
[No Abstract] [Full Text] [Related]
6. Efficacy of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Aziz M; Haghbin H; Gangwani M; Aziz A; Dahiya DS; Ali H; Lee-Smith W; Goyal H; Kamal F
Am J Ther; 2024 Jan-Feb 01; 31(1):e43-e45. PubMed ID: 38231581
[No Abstract] [Full Text] [Related]
7. Dupilumab (Dupixent) for eosinophilic esophagitis and prurigo nodularis.
Med Lett Drugs Ther; 2023 Feb; 65(1669):18-20. PubMed ID: 36757348
[No Abstract] [Full Text] [Related]
8. As Easy as EoE: A Novel and Effective Multidisciplinary Approach to Care of Patients with Eosinophilic Esophagitis in the Age of Biologics.
Chawla K; Alabbas B; Sheth D; Papademetriou M
Dig Dis Sci; 2020 Aug; 65(8):2196-2202. PubMed ID: 32519139
[No Abstract] [Full Text] [Related]
9. Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome.
Dixit C; Thatayatikom A; Pappa H; Knutsen AP
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4167-4169. PubMed ID: 34280586
[No Abstract] [Full Text] [Related]
10. Expanding the paradigm of eosinophilic esophagitis: mast cells and IL-9.
Wang YH; Hogan SP; Fulkerson PC; Abonia JP; Rothenberg ME
J Allergy Clin Immunol; 2013 Jun; 131(6):1583-5. PubMed ID: 23726533
[No Abstract] [Full Text] [Related]
11. Dupilumab: The New Kid on the Block for Management of Eosinophilic Esophagitis.
Yadlapati R
Gastroenterology; 2023 Jul; 165(1):302-303. PubMed ID: 36801387
[No Abstract] [Full Text] [Related]
12. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
13. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis.
Nguyen N; Burger C; Skirka S; White S; Smith M; Menard-Katcher C; Furuta GT; Mehta P
J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):536-539. PubMed ID: 37491718
[TBL] [Abstract][Full Text] [Related]
14. The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.
Nhu QM; Chiao H; Moawad FJ; Bao F; Konijeti GG
Am J Gastroenterol; 2018 Aug; 113(8):1261-1263. PubMed ID: 29895980
[No Abstract] [Full Text] [Related]
15. Omalizumab in the treatment of eosinophilic esophagitis and food allergy.
Rocha R; Vitor AB; Trindade E; Lima R; Tavares M; Lopes J; Dias JA
Eur J Pediatr; 2011 Nov; 170(11):1471-4. PubMed ID: 21809010
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
Clayton F; Fang JC; Gleich GJ; Lucendo AJ; Olalla JM; Vinson LA; Lowichik A; Chen X; Emerson L; Cox K; O'Gorman MA; Peterson KA
Gastroenterology; 2014 Sep; 147(3):602-9. PubMed ID: 24907494
[TBL] [Abstract][Full Text] [Related]
17. Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab.
Beales ILP
Dig Dis Sci; 2019 Sep; 64(9):2688-2689. PubMed ID: 31190203
[No Abstract] [Full Text] [Related]
18. Eosinophilic Gastritis/Gastroenteritis.
Chen PH; Anderson L; Zhang K; Weiss GA
Curr Gastroenterol Rep; 2021 Jul; 23(8):13. PubMed ID: 34331146
[TBL] [Abstract][Full Text] [Related]
19. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
[Next] [New Search]
